Bio-Techne(TECH) Prnewswire·2025-02-20 12:00Core Insights - Bio-Techne has launched an expanded menu of RNAscope™ in situ hybridization probes, enhancing spatial biology research and the development of next-generation therapeutics and diagnostics [1][3] - The RNAscope technology is recognized as the most referenced in the spatial biology industry, providing detailed insights into disease pathology and therapeutic responses [2] - The expanded RNAscope probe portfolio now includes over 70,000 unique probes across more than 450 species, facilitating the validation of new RNA biomarkers [1][3] Company Overview - Bio-Techne Corporation is a global leader in life sciences, generating approximately $1.2 billion in net sales in fiscal 2024 and employing around 3,100 people worldwide [4] - The company focuses on providing innovative tools and bioactive reagents for research and clinical diagnostics, aiding in drug discovery and accurate clinical testing [4] - The RNAscope probe portfolio has over 12,000 citations in clinical and translational research, underscoring its significance in advancing biomarker validation [4]